NO328650B1 - Propenkarboksylsyreamidoksimderivater, fremgangsmate for deres fremstilling, anvendelse av dem for fremstilling av medikamenter og farmasoytiske sammensetninger som inneholder nevnte derivater - Google Patents

Propenkarboksylsyreamidoksimderivater, fremgangsmate for deres fremstilling, anvendelse av dem for fremstilling av medikamenter og farmasoytiske sammensetninger som inneholder nevnte derivater Download PDF

Info

Publication number: NO328650B1
Authority: NO; Norway
Prior art keywords: formula; group; derivative; atom; reacted
Prior art date: 2000-03-20

Application number

NO20024341A

Other languages

English (en)

Norwegian (no)

Other versions

NO20024341L (no

NO20024341D0 (no

Inventor

Kalman Takacs

Balazs Suemegi

Peter Literati Nagy

Original Assignee

N Gene Res Lab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-20

Filing date

2002-09-11

Publication date

2010-04-19

2000-03-20 Priority claimed from HU0001178A external-priority patent/HU0001178D0/hu

2001-03-07 Priority claimed from HU0100987A external-priority patent/HU227116B1/hu

2002-09-11 Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc

2002-09-11 Publication of NO20024341D0 publication Critical patent/NO20024341D0/no

2002-11-20 Publication of NO20024341L publication Critical patent/NO20024341L/no

2010-04-19 Publication of NO328650B1 publication Critical patent/NO328650B1/no

Links

-1 Propylene carboxylic acid Chemical class 0.000 title claims abstract description 101
238000000034 method Methods 0.000 title claims description 60
238000002360 preparation method Methods 0.000 title claims description 37
239000003814 drug Substances 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 title claims description 10
230000008569 process Effects 0.000 title claims description 9
150000002923 oximes Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 203
239000002253 acid Substances 0.000 claims abstract description 60
150000003839 salts Chemical class 0.000 claims abstract description 55
238000011282 treatment Methods 0.000 claims abstract description 50
150000001204 N-oxides Chemical class 0.000 claims abstract description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
201000010099 disease Diseases 0.000 claims abstract description 35
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims abstract description 31
230000003287 optical effect Effects 0.000 claims abstract description 24
230000005764 inhibitory process Effects 0.000 claims abstract description 15
230000004770 neurodegeneration Effects 0.000 claims abstract description 13
208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 13
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 11
230000001363 autoimmune Effects 0.000 claims abstract description 11
231100000331 toxic Toxicity 0.000 claims abstract description 10
230000002588 toxic effect Effects 0.000 claims abstract description 10
230000003612 virological effect Effects 0.000 claims abstract description 9
PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical compound O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 claims description 51
125000004430 oxygen atom Chemical group O* 0.000 claims description 36
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 35
125000004433 nitrogen atom Chemical group N* 0.000 claims description 34
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
125000005843 halogen group Chemical group 0.000 claims description 29
229910052757 nitrogen Inorganic materials 0.000 claims description 27
JKNSMBZZZFGYCB-UHFFFAOYSA-N 4,5-dihydrooxadiazole Chemical class C1CN=NO1 JKNSMBZZZFGYCB-UHFFFAOYSA-N 0.000 claims description 23
125000000217 alkyl group Chemical group 0.000 claims description 18
229910052760 oxygen Inorganic materials 0.000 claims description 18
239000001301 oxygen Substances 0.000 claims description 18
125000001424 substituent group Chemical group 0.000 claims description 16
229910052717 sulfur Chemical group 0.000 claims description 16
125000004434 sulfur atom Chemical group 0.000 claims description 16
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
150000001412 amines Chemical class 0.000 claims description 14
239000004480 active ingredient Substances 0.000 claims description 13
125000000623 heterocyclic group Chemical group 0.000 claims description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
230000006735 deficit Effects 0.000 claims description 12
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 11
SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims description 11
HBJUQLMVCIEESP-UHFFFAOYSA-N 2,5-dihydro-1,2,4-oxadiazole Chemical class C1NC=NO1 HBJUQLMVCIEESP-UHFFFAOYSA-N 0.000 claims description 9
239000011230 binding agent Substances 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 9
150000004820 halides Chemical class 0.000 claims description 9
229910001854 alkali hydroxide Inorganic materials 0.000 claims description 8
150000008044 alkali metal hydroxides Chemical class 0.000 claims description 8
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 6
150000001350 alkyl halides Chemical group 0.000 claims description 6
125000004414 alkyl thio group Chemical group 0.000 claims description 6
230000002140 halogenating effect Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
150000005063 oxadiazines Chemical class 0.000 claims description 6
150000002924 oxiranes Chemical class 0.000 claims description 6
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 5
239000002585 base Substances 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
239000000969 carrier Substances 0.000 claims description 5
150000007524 organic acids Chemical class 0.000 claims description 5
239000007800 oxidant agent Substances 0.000 claims description 5
229940100198 alkylating agent Drugs 0.000 claims description 4
239000002168 alkylating agent Substances 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 4
125000004423 acyloxy group Chemical group 0.000 claims description 3
150000001447 alkali salts Chemical class 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
150000007522 mineralic acids Chemical class 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
235000013985 cinnamic acid Nutrition 0.000 claims description 2
229930016911 cinnamic acid Natural products 0.000 claims description 2
150000001923 cyclic compounds Chemical class 0.000 claims description 2
229910052740 iodine Inorganic materials 0.000 claims description 2
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
206010021143 Hypoxia Diseases 0.000 abstract description 25
230000007812 deficiency Effects 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 60
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 57
239000000243 solution Substances 0.000 description 52
241001465754 Metazoa Species 0.000 description 50
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 48
210000004027 cell Anatomy 0.000 description 48
230000000694 effects Effects 0.000 description 44
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 42
238000006243 chemical reaction Methods 0.000 description 38
102000004190 Enzymes Human genes 0.000 description 36
108090000790 Enzymes Proteins 0.000 description 36
239000011541 reaction mixture Substances 0.000 description 35
238000012360 testing method Methods 0.000 description 35
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 27
229960004316 cisplatin Drugs 0.000 description 26
230000002829 reductive effect Effects 0.000 description 26
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
238000002844 melting Methods 0.000 description 23
230000008018 melting Effects 0.000 description 23
239000003960 organic solvent Substances 0.000 description 23
238000005160 1H NMR spectroscopy Methods 0.000 description 22
239000002904 solvent Substances 0.000 description 22
102000004877 Insulin Human genes 0.000 description 21
108090001061 Insulin Proteins 0.000 description 21
206010022489 Insulin Resistance Diseases 0.000 description 21
229940125396 insulin Drugs 0.000 description 21
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
230000007954 hypoxia Effects 0.000 description 19
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 18
239000000203 mixture Substances 0.000 description 17
FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 17
230000001953 sensory effect Effects 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
238000002474 experimental method Methods 0.000 description 16
108020004414 DNA Proteins 0.000 description 15
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 15
230000006378 damage Effects 0.000 description 15
239000000825 pharmaceutical preparation Substances 0.000 description 15
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 14
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 14
229910000041 hydrogen chloride Inorganic materials 0.000 description 14
230000001965 increasing effect Effects 0.000 description 14
210000002966 serum Anatomy 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
238000011161 development Methods 0.000 description 13
239000008103 glucose Substances 0.000 description 13
238000011835 investigation Methods 0.000 description 13
230000007830 nerve conduction Effects 0.000 description 13
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
102100034343 Integrase Human genes 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 11
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
SENPVEZBRZQVST-HISDBWNOSA-N deamido-NAD zwitterion Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 SENPVEZBRZQVST-HISDBWNOSA-N 0.000 description 11
229960005489 paracetamol Drugs 0.000 description 11
208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
208000018737 Parkinson disease Diseases 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
230000000875 corresponding effect Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 10
208000028867 ischemia Diseases 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
239000000047 product Substances 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
230000004913 activation Effects 0.000 description 9
230000037396 body weight Effects 0.000 description 9
239000002158 endotoxin Substances 0.000 description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
210000005036 nerve Anatomy 0.000 description 9
229960003753 nitric oxide Drugs 0.000 description 9
230000001988 toxicity Effects 0.000 description 9
231100000419 toxicity Toxicity 0.000 description 9
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 8
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
239000007795 chemical reaction product Substances 0.000 description 8
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 8
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
230000014509 gene expression Effects 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 8
229960001052 streptozocin Drugs 0.000 description 8
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
239000004215 Carbon black (E152) Substances 0.000 description 7
102000002812 Heat-Shock Proteins Human genes 0.000 description 7
108010004889 Heat-Shock Proteins Proteins 0.000 description 7
102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
108060001084 Luciferase Proteins 0.000 description 7
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 7
150000004945 aromatic hydrocarbons Chemical class 0.000 description 7
238000009835 boiling Methods 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
230000030833 cell death Effects 0.000 description 7
230000009931 harmful effect Effects 0.000 description 7
229930195733 hydrocarbon Natural products 0.000 description 7
150000002430 hydrocarbons Chemical class 0.000 description 7
230000000260 hypercholesteremic effect Effects 0.000 description 7
210000002161 motor neuron Anatomy 0.000 description 7
210000004165 myocardium Anatomy 0.000 description 7
125000004076 pyridyl group Chemical group 0.000 description 7
230000010410 reperfusion Effects 0.000 description 7
239000007858 starting material Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
230000027455 binding Effects 0.000 description 6
210000001715 carotid artery Anatomy 0.000 description 6
239000013078 crystal Substances 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
230000006870 function Effects 0.000 description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
230000000302 ischemic effect Effects 0.000 description 6
229920006008 lipopolysaccharide Polymers 0.000 description 6
239000011976 maleic acid Substances 0.000 description 6
238000005259 measurement Methods 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
230000004044 response Effects 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
PQCAUHUKTBHUSA-UHFFFAOYSA-N 7-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1NN=C2 PQCAUHUKTBHUSA-UHFFFAOYSA-N 0.000 description 5
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
201000006474 Brain Ischemia Diseases 0.000 description 5
206010008120 Cerebral ischaemia Diseases 0.000 description 5
108010021188 Superoxide Dismutase-1 Proteins 0.000 description 5
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 5
206010008118 cerebral infarction Diseases 0.000 description 5
230000008602 contraction Effects 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000002440 hepatic effect Effects 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
230000036542 oxidative stress Effects 0.000 description 5
230000003950 pathogenic mechanism Effects 0.000 description 5
208000033808 peripheral neuropathy Diseases 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
SRNWOUGRCWSEMX-UHFFFAOYSA-N Adenosine diphosphate ribose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OCC1OC(O)C(O)C1O SRNWOUGRCWSEMX-UHFFFAOYSA-N 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
206010061216 Infarction Diseases 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
241000699684 Meriones unguiculatus Species 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
102000003945 NF-kappa B Human genes 0.000 description 4
108010057466 NF-kappa B Proteins 0.000 description 4
102000008221 Superoxide Dismutase-1 Human genes 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
229960004373 acetylcholine Drugs 0.000 description 4
238000005576 amination reaction Methods 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000008859 change Effects 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000003053 immunization Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
201000001119 neuropathy Diseases 0.000 description 4
230000007823 neuropathy Effects 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
238000006213 oxygenation reaction Methods 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
230000004224 protection Effects 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
230000011514 reflex Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
LDHQCZJRKDOVOX-UHFFFAOYSA-N 2-butenoic acid Chemical compound CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108010024636 Glutathione Proteins 0.000 description 3
206010019851 Hepatotoxicity Diseases 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
206010067125 Liver injury Diseases 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
239000012661 PARP inhibitor Substances 0.000 description 3
206010033799 Paralysis Diseases 0.000 description 3
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
102000007156 Resistin Human genes 0.000 description 3
108010047909 Resistin Proteins 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
210000001789 adipocyte Anatomy 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003610 charcoal Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000001120 cytoprotective effect Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
210000003038 endothelium Anatomy 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
229960003180 glutathione Drugs 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
231100000234 hepatic damage Toxicity 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
231100000304 hepatotoxicity Toxicity 0.000 description 3
230000007686 hepatotoxicity Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000007574 infarction Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000010354 integration Effects 0.000 description 3
231100000225 lethality Toxicity 0.000 description 3
230000008818 liver damage Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
230000035772 mutation Effects 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
229960000689 nevirapine Drugs 0.000 description 3
235000005152 nicotinamide Nutrition 0.000 description 3
239000011570 nicotinamide Substances 0.000 description 3
229960002748 norepinephrine Drugs 0.000 description 3
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
239000002777 nucleoside Substances 0.000 description 3
229940127073 nucleoside analogue Drugs 0.000 description 3
150000003833 nucleoside derivatives Chemical class 0.000 description 3
150000002927 oxygen compounds Chemical class 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000002040 relaxant effect Effects 0.000 description 3
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
239000000523 sample Substances 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
238000003756 stirring Methods 0.000 description 3
210000003523 substantia nigra Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
150000005065 1,2,4-oxadiazines Chemical class 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
UFFBMTHBGFGIHF-UHFFFAOYSA-N 2,6-dimethylaniline Chemical compound CC1=CC=CC(C)=C1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 2
108090000312 Calcium Channels Proteins 0.000 description 2
102000003922 Calcium Channels Human genes 0.000 description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
241001573498 Compacta Species 0.000 description 2
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
102000003849 Cytochrome P450 Human genes 0.000 description 2
230000005778 DNA damage Effects 0.000 description 2
231100000277 DNA damage Toxicity 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 2
101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
241000713869 Moloney murine leukemia virus Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
238000011785 NMRI mouse Methods 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
206010034277 Pemphigoid Diseases 0.000 description 2
206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
108091026813 Poly(ADPribose) Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
230000036982 action potential Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003288 anthiarrhythmic effect Effects 0.000 description 2
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000036765 blood level Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
230000001364 causal effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
230000007123 defense Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
210000005064 dopaminergic neuron Anatomy 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
230000000667 effect on insulin Effects 0.000 description 2
230000005684 electric field Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000835 fiber Substances 0.000 description 2
230000002600 fibrillogenic effect Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
238000005658 halogenation reaction Methods 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
229960003350 isoniazid Drugs 0.000 description 2
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000004899 motility Effects 0.000 description 2
230000002635 muscarinergic effect Effects 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
210000004457 myocytus nodalis Anatomy 0.000 description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000005876 negative regulation of fatty acid oxidation Effects 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
230000016273 neuron death Effects 0.000 description 2
230000003961 neuronal insult Effects 0.000 description 2
229960003966 nicotinamide Drugs 0.000 description 2
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
230000001883 nitrergic effect Effects 0.000 description 2
150000002829 nitrogen Chemical class 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
230000004526 pharmaceutical effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000000291 postprandial effect Effects 0.000 description 2
238000003825 pressing Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
210000004129 prosencephalon Anatomy 0.000 description 2
235000008160 pyridoxine Nutrition 0.000 description 2
239000011677 pyridoxine Substances 0.000 description 2
238000005956 quaternization reaction Methods 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
102220020162 rs397508045 Human genes 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
230000035939 shock Effects 0.000 description 2
101150062190 sod1 gene Proteins 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
230000035882 stress Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
230000000304 vasodilatating effect Effects 0.000 description 2
208000003663 ventricular fibrillation Diseases 0.000 description 2
206010047302 ventricular tachycardia Diseases 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
229940011671 vitamin b6 Drugs 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
239000008096 xylene Substances 0.000 description 2
125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical class C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 1
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
OBOBUDMMFXRNDO-UHFFFAOYSA-N 1-(3-chloropropyl)piperidine;hydron;chloride Chemical compound Cl.ClCCCN1CCCCC1 OBOBUDMMFXRNDO-UHFFFAOYSA-N 0.000 description 1
YMUIALJGRCXTBP-UHFFFAOYSA-N 1-chloro-3-piperidin-1-ylpropan-2-ol;hydrochloride Chemical compound Cl.ClCC(O)CN1CCCCC1 YMUIALJGRCXTBP-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
TZDPJNSHSWMCPN-UHFFFAOYSA-N 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC([N+]([O-])=O)=C1 TZDPJNSHSWMCPN-UHFFFAOYSA-N 0.000 description 1
FCKYPQBAHLOOJQ-NXEZZACHSA-N 2-[[(1r,2r)-2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)[C@@H]1CCCC[C@H]1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-NXEZZACHSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical group N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
YOGBMCNYVFIMJS-UHFFFAOYSA-N 5,6-dihydro-2h-1,2,4-oxadiazine Chemical class C1CON=CN1 YOGBMCNYVFIMJS-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
206010003175 Arterial spasm Diseases 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
206010061666 Autonomic neuropathy Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000012639 Balance disease Diseases 0.000 description 1
108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006100 Bradykinesia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000001778 Coronary Occlusion Diseases 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000003915 DNA Topoisomerases Human genes 0.000 description 1
108090000323 DNA Topoisomerases Proteins 0.000 description 1
MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000001034 Frostbite Diseases 0.000 description 1
LFBZZHVSGAHQPP-UHFFFAOYSA-N GYKI 52466 Chemical compound C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C(N)C=C1 LFBZZHVSGAHQPP-UHFFFAOYSA-N 0.000 description 1
108091052347 Glucose transporter family Proteins 0.000 description 1
JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 1
101100149812 Homo sapiens SOD1 gene Proteins 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010061833 Integrases Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
229910019440 Mg(OH) Inorganic materials 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
208000021908 Myocardial disease Diseases 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
229940127397 Poly(ADP-Ribose) Polymerase Inhibitors Drugs 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
241001340896 Pyralis Species 0.000 description 1
206010058156 Reperfusion arrhythmia Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
108700043492 SprD Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
108010073976 UDP-GlcNAc-undecaprenyl phosphate N-acetylglucosaminyl 1-phosphate transferase Proteins 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
229960004266 acetylcholine chloride Drugs 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
230000008649 adaptation response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000003513 alkali Substances 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003257 anti-anginal effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940127003 anti-diabetic drug Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000001741 anti-phlogistic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000011138 biotechnological process Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001767 chemoprotection Effects 0.000 description 1
208000037516 chromosome inversion disease Diseases 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
229950009226 ciglitazone Drugs 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000009989 contractile response Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000002089 crippling effect Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
229960000860 dapsone Drugs 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
229940120124 dichloroacetate Drugs 0.000 description 1
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229960002563 disulfiram Drugs 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
229960002001 ethionamide Drugs 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
230000001610 euglycemic effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
108010014487 geranylpyrophosphate olivetolate geranyltransferase Proteins 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
229960002972 glutethimide Drugs 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000012010 growth Effects 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
230000002443 hepatoprotective effect Effects 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
230000000910 hyperinsulinemic effect Effects 0.000 description 1
230000035873 hypermotility Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
150000002465 imidoyl halides Chemical class 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
208000037906 ischaemic injury Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000003908 liver function Effects 0.000 description 1
231100000149 liver necrosis Toxicity 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000008035 nerve activity Effects 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000002644 neurohormonal effect Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
239000002840 nitric oxide donor Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
230000001129 nonadrenergic effect Effects 0.000 description 1
230000002536 noncholinergic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
231100000927 organotoxic Toxicity 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
101150063226 parp-1 gene Proteins 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000003614 peroxisome proliferator Substances 0.000 description 1
150000004965 peroxy acids Chemical class 0.000 description 1
CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
230000009038 pharmacological inhibition Effects 0.000 description 1
230000000079 pharmacotherapeutic effect Effects 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
PZQSQRCNMZGWFT-QXMHVHEDSA-N propan-2-yl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)C PZQSQRCNMZGWFT-QXMHVHEDSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000002763 pyramidal cell Anatomy 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000013333 regulation of fatty acid metabolic process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000003571 reporter gene assay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000020874 response to hypoxia Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
238000010825 rotarod performance test Methods 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
230000025185 skeletal muscle atrophy Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
238000009751 slip forming Methods 0.000 description 1
229960001315 sodium aurothiomalate Drugs 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
AUZONCFQVSMFAP-UHFFFAOYSA-N tetraethylthiuram disulfide Natural products CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
150000003548 thiazolidines Chemical class 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
150000003565 thiocarboxylic acid derivatives Chemical class 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000017105 transposition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
239000012989 trithiocarbonate Substances 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Dermatology (AREA)
Immunology (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)

NO20024341A 2000-03-20 2002-09-11 Propenkarboksylsyreamidoksimderivater, fremgangsmate for deres fremstilling, anvendelse av dem for fremstilling av medikamenter og farmasoytiske sammensetninger som inneholder nevnte derivater NO328650B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
HU0001178A HU0001178D0 (en)	2000-03-20	2000-03-20	New propene-carbon acid-amidoxim derivatives, process for their production and medicaments containing the same
HU0100987A HU227116B1 (en)	2001-03-07	2001-03-07	New propenecarboxylic acid amidoxime derivatives, process for their preparation and pharmaceutical compositions containing them
PCT/HU2001/000029 WO2001070674A1 (en)	2000-03-20	2001-03-13	Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same

Publications (3)

Publication Number	Publication Date
NO20024341D0 NO20024341D0 (no)	2002-09-11
NO20024341L NO20024341L (no)	2002-11-20
NO328650B1 true NO328650B1 (no)	2010-04-19

Family

ID=89979102

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20024341A NO328650B1 (no)	2000-03-20	2002-09-11	Propenkarboksylsyreamidoksimderivater, fremgangsmate for deres fremstilling, anvendelse av dem for fremstilling av medikamenter og farmasoytiske sammensetninger som inneholder nevnte derivater

Country Status (25)

Country	Link
US (2)	US6887872B2 (pl)
EP (1)	EP1268407B1 (pl)
JP (1)	JP2003528073A (pl)
KR (1)	KR100679364B1 (pl)
CN (1)	CN1232503C (pl)
AT (1)	ATE265998T1 (pl)
AU (1)	AU783393B2 (pl)
BR (1)	BR0109430A (pl)
CA (1)	CA2404128C (pl)
CZ (1)	CZ20023110A3 (pl)
DE (1)	DE60103140T2 (pl)
DK (1)	DK1268407T3 (pl)
ES (1)	ES2220753T3 (pl)
HK (1)	HK1053826B (pl)
IL (1)	IL151669A0 (pl)
MX (1)	MXPA02009216A (pl)
NO (1)	NO328650B1 (pl)
NZ (1)	NZ521792A (pl)
PL (1)	PL358393A1 (pl)
PT (1)	PT1268407E (pl)
RU (1)	RU2264387C2 (pl)
SI (1)	SI1268407T1 (pl)
SK (1)	SK287101B6 (pl)
TR (1)	TR200401912T4 (pl)
WO (1)	WO2001070674A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040151785A1 (en) *	1998-10-06	2004-08-05	Diamedica Inc.	Method for treating insulin resistance through hepatic nitric oxide
EP1663202A1 (en) *	2003-09-04	2006-06-07	Aventis Pharmaceuticals, Inc.	Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
JPWO2006137510A1 (ja) *	2005-06-24	2009-01-22	小野薬品工業株式会社	脳血管障害時における出血低減剤
DE102006050516A1 (de) *	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dihydropyrazolone und ihre Verwendung
CA2689948A1 (en) *	2007-06-01	2008-12-18	Schering Corporation	Gamma secretase modulators
WO2008154129A1 (en) *	2007-06-08	2008-12-18	Bausch & Lomb Incorporated	Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
AU2009314205A1 (en)	2008-11-13	2010-05-20	Merck Sharp & Dohme Corp.	Gamma secretase modulators
HUP1100445A2 (en)	2011-08-17	2013-02-28	Pharma Gene Sa	Pharmaceutical composition
HUP1100444A2 (en)	2011-08-17	2013-02-28	Pharma Gene Sa	Pharmaceutical composition
WO2013173923A1 (en)	2012-05-25	2013-11-28	Diamedica, Inc.	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en)	2012-06-04	2017-02-22	Diamedica Inc.	Human tissue kallikrein 1 glycosylation isoforms
WO2015084752A1 (en) *	2013-12-04	2015-06-11	Merck Sharp & Dohme Corp.	Gamma secretase modulators
FR3035105A1 (fr) *	2015-04-16	2016-10-21	Metabrain Res	Derives utiles dans le traitement de l'atrophie musculaire
US11857608B2 (en)	2017-03-09	2024-01-02	Diamedica Inc.	Dosage forms of tissue kallikrein 1
HUP1800298A1 (hu)	2018-08-30	2020-05-28	N Gene Res Laboratories Inc	Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN112107594B (zh) *	2020-09-29	2021-10-26	苏州大学	共价有机纳米片材料的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4308399A (en) *	1977-08-30	1981-12-29	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU179951B (en) *	1979-10-11	1983-01-28	Chinoin Gyogyszer Es Vegyeszet	Process for preparing 1,2,4-oxadiazolin-5-one derivatives and pharmaceutical compositions containing thereof
EP0039861B1 (de) *	1980-05-12	1984-08-15	Henkel Kommanditgesellschaft auf Aktien	Verfahren zum Abbau der 20-Carboxylgruppe in delta-1,4-BNC und verwandten Steroidverbindungen sowie neue stickstoffhaltige C-21-Steroidverbindungen
HUT54347A (en) *	1989-01-10	1991-02-28	Chinoin Gyogyszer Es Vegyeszet	Improved process for producing amidoximes
GB9702701D0 (en) *	1997-02-01	1997-04-02	Univ Newcastle Ventures Ltd	Quinazolinone compounds
US6291425B1 (en) *	1999-09-01	2001-09-18	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
UA65635C2 (uk) *	1998-09-03	2004-04-15	Н-Гене Кутато Кфт.	НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
ATE261963T1 (de) *	1999-01-11	2004-04-15	Agouron Pharma	Tricyclische inhibitoren von poly(adp-ribose) polymerasen
DE19920936A1 (de) *	1999-05-07	2000-11-09	Basf Ag	Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE19921567A1 (de) *	1999-05-11	2000-11-16	Basf Ag	Verwendung von Phthalazine-Derivaten

2001
- 2001-03-13 PL PL01358393A patent/PL358393A1/pl not_active IP Right Cessation
- 2001-03-13 AU AU46744/01A patent/AU783393B2/en not_active Ceased
- 2001-03-13 AT AT01919683T patent/ATE265998T1/de not_active IP Right Cessation
- 2001-03-13 CZ CZ20023110A patent/CZ20023110A3/cs unknown
- 2001-03-13 SK SK1350-2002A patent/SK287101B6/sk not_active IP Right Cessation
- 2001-03-13 ES ES01919683T patent/ES2220753T3/es not_active Expired - Lifetime
- 2001-03-13 MX MXPA02009216A patent/MXPA02009216A/es active IP Right Grant
- 2001-03-13 DK DK01919683T patent/DK1268407T3/da active
- 2001-03-13 US US10/239,159 patent/US6887872B2/en not_active Expired - Fee Related
- 2001-03-13 PT PT01919683T patent/PT1268407E/pt unknown
- 2001-03-13 KR KR1020027012374A patent/KR100679364B1/ko not_active IP Right Cessation
- 2001-03-13 IL IL15166901A patent/IL151669A0/xx not_active IP Right Cessation
- 2001-03-13 JP JP2001568886A patent/JP2003528073A/ja not_active Ceased
- 2001-03-13 DE DE60103140T patent/DE60103140T2/de not_active Expired - Lifetime
- 2001-03-13 WO PCT/HU2001/000029 patent/WO2001070674A1/en active IP Right Grant
- 2001-03-13 TR TR2004/01912T patent/TR200401912T4/xx unknown
- 2001-03-13 NZ NZ521792A patent/NZ521792A/en unknown
- 2001-03-13 SI SI200130149T patent/SI1268407T1/xx unknown
- 2001-03-13 EP EP01919683A patent/EP1268407B1/en not_active Expired - Lifetime
- 2001-03-13 RU RU2002127802/04A patent/RU2264387C2/ru not_active IP Right Cessation
- 2001-03-13 CN CNB018084400A patent/CN1232503C/zh not_active Expired - Fee Related
- 2001-03-13 CA CA2404128A patent/CA2404128C/en not_active Expired - Fee Related
- 2001-03-13 BR BR0109430-0A patent/BR0109430A/pt not_active Application Discontinuation
2002
- 2002-09-11 NO NO20024341A patent/NO328650B1/no not_active IP Right Cessation
2003
- 2003-07-02 HK HK03104718.0A patent/HK1053826B/zh not_active IP Right Cessation
2005
- 2005-03-21 US US11/084,231 patent/US7151175B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL151669A0 (en)	2003-04-10
US20050165019A1 (en)	2005-07-28
DE60103140T2 (de)	2005-05-04
RU2264387C2 (ru)	2005-11-20
SK13502002A3 (sk)	2003-02-04
BR0109430A (pt)	2002-12-10
CA2404128C (en)	2011-01-04
NZ521792A (en)	2004-06-25
PT1268407E (pt)	2004-11-30
NO20024341L (no)	2002-11-20
DE60103140D1 (de)	2004-06-09
JP2003528073A (ja)	2003-09-24
ES2220753T3 (es)	2004-12-16
US20030153559A1 (en)	2003-08-14
MXPA02009216A (es)	2003-12-11
PL358393A1 (pl)	2004-08-09
US6887872B2 (en)	2005-05-03
CA2404128A1 (en)	2001-09-27
TR200401912T4 (tr)	2004-09-21
EP1268407B1 (en)	2004-05-06
HK1053826B (zh)	2005-01-14
AU783393B2 (en)	2005-10-20
ATE265998T1 (de)	2004-05-15
CZ20023110A3 (cs)	2003-02-12
NO20024341D0 (no)	2002-09-11
KR20020091144A (ko)	2002-12-05
CN1426392A (zh)	2003-06-25
WO2001070674A1 (en)	2001-09-27
SK287101B6 (sk)	2009-12-07
DK1268407T3 (da)	2004-09-06
CN1232503C (zh)	2005-12-21
EP1268407A1 (en)	2003-01-02
KR100679364B1 (ko)	2007-02-05
US7151175B2 (en)	2006-12-19
AU4674401A (en)	2001-10-03
SI1268407T1 (en)	2004-10-31
HK1053826A1 (en)	2003-11-07

Publication	Publication Date	Title
NO328650B1 (no)	2010-04-19	Propenkarboksylsyreamidoksimderivater, fremgangsmate for deres fremstilling, anvendelse av dem for fremstilling av medikamenter og farmasoytiske sammensetninger som inneholder nevnte derivater
US5326770A (en)	1994-07-05	Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
JP3188715B2 (ja)	2001-07-16	一酸化窒素シンターゼの阻害物質としてのヘキサヒドロ−５−イミノ−１，４−ヘテロアゼピン誘導体
US6500823B1 (en)	2002-12-31	Unsaturated hydroximic acid derivatives as per abstract inhibitors
DE69516257T2 (de)	2000-09-28	1,4-Benzoxazinderivate, es enthaltende pharmazeutische Zusammensetzung und seine Verwendung
HU227116B1 (en)	2010-07-28	New propenecarboxylic acid amidoxime derivatives, process for their preparation and pharmaceutical compositions containing them
DK151629B (da)	1987-12-21	Analogifremgangsmaade til fremstilling af 3-amino-1-benzoxepin-5(2h)-on-derivater eller syreadditionssalte deraf
UA73557C2 (en)	2005-08-15	Amideoxyme derivatives of propenecarboxylic acid, a method for the preparation thereof and a pharmaceutical composition based thereon
US20050203176A1 (en)	2005-09-15	Carbamates as HIV anti-viral agents
SE202335C1 (pl)	1965-01-01

Legal Events

Date	Code	Title	Description
2011-10-24	MM1K	Lapsed by not paying the annual fees